ArticleESMO open2026

APOBEC mutational signatures predict immune checkpoint inhibitor benefit in TMB-low metastatic NSCLC independent of PD-L1 status.

A Yaacov et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.